WO2016000608A1 - 一种阿利沙坦酯固体分散体及含有该固体分散体的药物组合物 - Google Patents

一种阿利沙坦酯固体分散体及含有该固体分散体的药物组合物 Download PDF

Info

Publication number
WO2016000608A1
WO2016000608A1 PCT/CN2015/082994 CN2015082994W WO2016000608A1 WO 2016000608 A1 WO2016000608 A1 WO 2016000608A1 CN 2015082994 W CN2015082994 W CN 2015082994W WO 2016000608 A1 WO2016000608 A1 WO 2016000608A1
Authority
WO
WIPO (PCT)
Prior art keywords
solid dispersion
pharmaceutical composition
albacetate
alisartan
preparation
Prior art date
Application number
PCT/CN2015/082994
Other languages
English (en)
French (fr)
Inventor
叶冠豪
卜水
Original Assignee
深圳信立泰药业股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 深圳信立泰药业股份有限公司 filed Critical 深圳信立泰药业股份有限公司
Priority to CA2949164A priority Critical patent/CA2949164A1/en
Priority to MX2016017142A priority patent/MX2016017142A/es
Priority to EP15814962.5A priority patent/EP3165219A4/en
Priority to US15/320,478 priority patent/US20170157095A1/en
Priority to JP2016575770A priority patent/JP6293315B2/ja
Priority to KR1020177000500A priority patent/KR101895962B1/ko
Priority to RU2017102990A priority patent/RU2017102990A/ru
Publication of WO2016000608A1 publication Critical patent/WO2016000608A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Definitions

  • the present invention is in the field of pharmaceutical preparations, and in particular, the present invention relates to a solid dispersion of alimentartan and a pharmaceutical composition containing the same.
  • Alisartanide (CAS: 947331-05-7), chemical name: 2-butyl-4-chloro-1-[2'-(1H-tetrazol-5-yl)-1,1'-biphenyl -Methyl]-imidazole-5-carboxylic acid, 1-[(isopropoxy)-carbonyloxy]-methyl ester, trade name: seletan, is a novel angiotensin II receptor antagonist .
  • Chinese patent CN200680000397.8 discloses the structural formula of the compound of alisartan, which is less toxic and has better antihypertensive effect than the same type of product (such as losartan), which is metabolized in the body to produce active metabolite (EXP3174). Its antihypertensive effect.
  • Alisartantan ester is an ester derivative of EXP3174, and its solubility in water is small, and the preparation obtained by the conventional preparation method is difficult to meet the clinical drug demand.
  • Chinese Patent CN200880001668.0 provides a pharmaceutical composition of alisartan, which effectively increases the dissolution of the active ingredient by adding a specific carrier and using a solid dispersion technique, Example D1
  • the -D6 results showed that the dissolution at 45 minutes was above 90%, which met the clinical drug requirements.
  • the formulation scheme in the prior art is insufficient, in that the solid dispersion is not loaded in a high amount, so that the active ingredient is low in the pharmaceutical composition, and the unit preparation quality is too large, so that the patient's medication compliance is poor.
  • the clinical drug quality and antihypertensive effect were not optimized.
  • the preparations with acceptable initial dissolution properties have a significant decrease in dissolution performance after storage for a period of time, and the aging phenomenon is particularly noticeable when the amount of the solid dispersion carrier is reduced. It can be seen that the speed and extent of aging of the solid dispersion is an important factor in evaluating the quality of the solid dispersion, and is also a factor that needs to be considered in the process of increasing the drug loading.
  • the present invention has found a new solid dispersion of alisartanide by a large number of experiments, which has the characteristics of high stability and good dissolution performance.
  • the solid dispersion effectively reduces the amount of the carrier by adding a surfactant, increases the drug loading of the solid dispersion, and further increases the content of the active ingredient in the preparation, and reduces the quality of the unit preparation.
  • the object of the present invention is to overcome the deficiencies of the prior art, and to ensure the stability of the preparation and the dissolution degree, by adding a surfactant, the content of the active ingredient in the solid dispersion is effectively increased, thereby finding a high load.
  • a solid dispersion of arsartantan ester having a higher drug loading than the prior art, and the pharmaceutical composition containing the solid dispersion has the characteristics of good dissolution property, good stability, and the like, and meets the requirements for clinical use, and The clinical drug quality and antihypertensive effect are optimized, and the patient's medication compliance is improved.
  • a solid dispersion of albacetate comprising alisartan and a pharmaceutically acceptable carrier material, the carrier material comprising a solubilizing carrier, characterized in that the solid dispersion of albacetate further comprises a surfactant, and The mass ratio of alisartanide to surfactant is from 1:0.01 to 0.10.
  • Surfactants are known in the art to refer to a class of materials which have a strong surface activity and which significantly reduce the surface tension of the liquid. According to the dissociation properties of polar groups, surfactants commonly used in the formulation field include anionic surfactants, cationic surfactants, zwitterionic surfactants, and nonionic surfactants.
  • anionic surfactants cationic surfactants
  • cationic surfactants cationic surfactants
  • zwitterionic surfactants zwitterionic surfactants
  • nonionic surfactants nonionic surfactants.
  • the addition of an appropriate amount of surfactant can improve the dissolution performance of the preparation and reduce the amount of solubilizing excipients used. More surprisingly, the inventors have found through experiments that for the alisartan ester compound, an appropriate amount of surfactant also has the effect of increasing the stability of the solid dispersion.
  • the surfactant is selected from anionic surfactants such as sodium lauryl sulfate, sodium cetyl sulfate, sodium stearyl sulfate; zwitterionic surfactants such as Lecithin (soy lecithin, egg yolk lecithin); nonionic surfactants such as polyol type (sucrose stearate), fatty acid sorbitan (span 20, 40, 60, 80), polysorbate (Tween) 20, 40, 60, 80), one or a mixture of two or more of polyoxyethylene fatty alcohol ethers (polyoxyethylene 35 castor oil, polyoxyethylene 40 hydrogenated castor oil), preferably sodium lauryl sulfate One or a mixture of two or more of lecithin (soy lecithin, egg yolk lecithin
  • the amount of surfactant used is related to the drug loading and stability of the solid dispersion.
  • the drug loading amount refers to the amount of the active ingredient supported per unit mass in the solid dispersion, and the higher the drug loading amount of the solid dispersion, the more technically difficult it is to achieve.
  • the addition of the surfactant can significantly improve the dissolution rate, reduce the amount of the carrier, and avoid the aging phenomenon, thereby achieving the effect of increasing the drug loading of the solid dispersion and reducing the quality of the unit preparation.
  • the surfactant increases, it plays a role in the improvement of dissolution and the increase of drug loading.
  • the inventors found through extensive experimental screening that the stability and dissolution of the solid dispersion are better when the mass ratio of the alexartrexate to the surfactant is 1:0.01 to 0.10, preferably 1:0.02 to 0.06. And the drug loading of the solid dispersion can be significantly improved.
  • the pharmaceutically acceptable carrier material of the present invention contains a solubilizing carrier.
  • the increase in the amount of the carrier material in the solid dispersion contributes to uniform and stable dispersion of the active ingredient, thereby improving the drug.
  • the difficulty in preparation of the solid dispersion is also reduced.
  • the amount of the carrier may be an amount which is known to those skilled in the art to achieve a solid dispersion loading effect.
  • the surfactant the amount of the carrier in the solid dispersion can be significantly reduced on the basis of ensuring the stability of the solid dispersion, thereby increasing the drug loading of the solid dispersion.
  • the solubilizing carrier of the present invention can serve as a carrier for dispersion, which refers to a series of pharmaceutical excipients having solubilization effect.
  • the solubilizing carrier is selected from the group consisting of povidone, copolyvidone and the like.
  • a homopolymer or copolymer of pyrrolidone polyvinyl alcohol; polyethylene glycol (PEG 4000, PEG 6000); cellulose ethers such as methyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose; Eugragit L 100 and Polyacrylic acid polymer such as S100, II, III acrylic resin; hydroxypropyl methylcellulose phthalate (HPMCP HP-55), cellulose acetate phthalate (CAP), hydroxypropyl a mixture of one or more of methylcellulose-cellulose acetate succinate (HPMCAS) and the like in any ratio, preferably povidone, copolyvidone, polyethylene glycol (PEG4000, PEG6000), hydroxypropyl One or a mixture of two or more of cellulose, hydroxypropylmethylcellulose, hydroxypropylmethylcellulose phthalate (HPMCP HP-55) mixed in any ratio.
  • the amount of solubilizing support facilitates the preparation of the solid dispersion, it also corresponds to a reduction in the drug loading of the solid dispersion.
  • the amount of solubilizing carrier used in the solid dispersion of albacetate can be significantly reduced, but the amount of the too low solubilizing carrier cannot achieve the dispersion effect, and thus the solid dispersion cannot be formed.
  • the inventors have found through a large number of experiments that on the basis of the addition of the surfactant, when the mass ratio of the albacetam and the solubilizing carrier is 1:0.15 to 0.5, preferably 1:0.20 to 0.30, it is advantageous. The optimization of the solid dispersion loading and the quality of the solid dispersion product is achieved.
  • the povidone is a 1-vinyl-2-pyrrolidone homopolymer, the specifications of which are classified by the average molecular weight: PVP k12, PVP k15, PVP k17, PVP k25, PVP k30, PVP k29/32, PVP k60, PVP k120, etc., preferably PVP k29/32.
  • the hydroxypropylcellulose is classified into HPC-SSL, HPC-SL, HPC-L, HPC-M, HPC-H or the like by an average molecular weight, preferably HPC-SL.
  • the hydroxypropylmethylcellulose is classified into E3, E5, E6, E15, E50Lv and the like by viscosity, and preferably HPMC E6.
  • the carrier material of the solid dispersion of the albacetate may further comprise an excipient which functions to carry and assist in dispersing the active ingredient, but too little The agent does not function to carry and assist dispersion, and too much excipient will also make the preparation quality too large, and at the same time, the preparation process will be complicated.
  • the shaping The agent may be a mixture of any one or more kinds of pharmaceutical excipients other than the solubilizing carrier and the surfactant, such as a disintegrating agent, a filler, a binder, and the like, in any ratio, and more specifically, the shaping The agent is selected from the group consisting of crospovidone, croscarmellose sodium, low-substituted hydroxypropylcellulose, sodium carboxymethyl starch, microcrystalline cellulose, starch, pregelatinized starch, lactose, dextrin, and nectar a mixture of one or more of an alcohol, calcium sulfate, calcium phosphate, calcium hydrogen phosphate or the like mixed in an arbitrary ratio, preferably crospovidone, which is a synthetic crosslinked N-vinyl group - 2-pyrrolidone homopolymer, available in PVPP XL, PVPP XL-10, etc.
  • the mass ratio of the alisartan and the excipient is 1:0.10 to 1.00,
  • the surfactant, solubilizing carrier and excipient can be selected among the corresponding species as described above, for example, a preferred embodiment of the solid dispersion of the present invention, which has the following composition:
  • the solid dispersion of albacetate can be prepared according to a specific prescription by a conventional preparation method in the art, such as a solvent method, a solvent deposition method, a spray drying method, a fluidized bed method, a freeze drying method, etc., preferably a fluidized bed. law.
  • the method for preparing a solid dispersion of alisartanide comprises the following steps:
  • the excipient is placed in a fluidized bed, and the drug solution is added by overhead spray, and fluidized bed spray granulation is carried out to obtain the solid dispersion of the alisartan mesylate.
  • Another object of the present invention is to provide a pharmaceutical composition of alimentartan which is composed of the solid dispersion of alimentate of the present invention and a pharmaceutically acceptable adjuvant.
  • the pharmaceutical excipient may contain one or a mixture of two or more of a disintegrant, a binder, a filler, a lubricant, and the like, as needed.
  • the disintegrant is selected from the group consisting of croscarmellose sodium, dry starch, crospovidone, sodium carboxymethyl starch, low-substituted hydroxypropyl cellulose, starch, pregelatinized starch, and the like. Or a mixture of multiples; the amount of disintegrant used is based on the amount of disintegration effect known in the art.
  • the use of an excessive disintegrant is not conducive to the control of the quality of the unit dosage form.
  • the use of too little disintegrant makes the disintegration of the composition too long, and the dissolution of the corresponding pharmaceutical composition cannot meet the requirements of clinical use.
  • the mass ratio of the solid dispersion to the disintegrant in the pharmaceutical composition is 1:0.02 to 0.20.
  • the binder may or may not be added depending on the formulation of the preparation.
  • the binder is selected from the group consisting of hydroxypropylmethylcellulose, hydroxypropylcellulose, sodium carboxymethylcellulose, povidone a mixture of one or more of starch syrup, gelatin, and the like.
  • the amount of the binder used is based on an amount known in the art to achieve an adhesive effect.
  • the mass ratio of the solid dispersion to the binder in the pharmaceutical composition is 1: 0.01 to 0.05.
  • the filler may be selected with or without addition depending on the formulation of the preparation.
  • the filler is selected from the group consisting of lactose, mannitol, dextrin, microcrystalline cellulose, starch, pregelatinized starch, calcium sulfate, and calcium phosphate.
  • a mixture of one or more of calcium hydrogen phosphate and the like, the amount of the filler used is based on an amount known in the art to achieve a filling effect, preferably, the solid dispersion and the filler in the pharmaceutical composition
  • the mass ratio is 1:0.02 to 0.20.
  • the lubricant is selected from the group consisting of a mixture of one or more of stearic acid, magnesium stearate, micronized silica gel, talc, polyethylene glycol, and the like, and the amount of lubricant used is such that it is known in the art to achieve a lubricating effect. The amount is subject to.
  • the pharmaceutical composition of alisartan is a conventional oral preparation such as a tablet, a capsule, a granule, or a pill, and is preferably a tablet or a capsule.
  • the pharmaceutical composition is prepared by a preparation method commonly used in the art. Specifically, for the tablet, it can be prepared by dry granulation or wet granulation, or can be prepared by direct pressure; for capsules, it can be dried. Method of granulation, wet granulation or direct filling with powder.
  • a specific scheme of the pharmaceutical composition of the alisartan mesylate of the present invention is as follows:
  • the solid dispersion obtained is uniformly mixed with the auxiliary material and directly pressed into a tablet. If necessary, it can be further coated to obtain coated tablets.
  • the alisartan mesylate pharmaceutical composition of the present invention can be used for the treatment of hypertension and its complications.
  • the alisartantan pharmaceutical composition can be used for the treatment of mild to moderate essential hypertension.
  • the hypertension complications refer to conditions caused by hypertension, including: cardiac complications such as left ventricular hypertrophy, angina pectoris, myocardial infarction, heart failure, etc.; stroke, such as hemorrhagic stroke, ischemic stroke, Hypertensive encephalopathy, etc.; hypertensive renal damage, such as slow progression of small arteriosclerosis, malignant small arteriosclerosis, chronic renal failure, etc.; ophthalmic diseases, such as retinal arteriosclerosis, fundus changes.
  • the present invention has the following outstanding advantages and beneficial effects:
  • a high-loading solid dispersion of alisartanide is provided by adding a surfactant
  • the solid dispersion has obvious advantages in terms of drug loading, dissolution performance, stability and the like compared with the prior art;
  • the drug and povidone k29/32 were dissolved in an appropriate amount of a dichloromethane-ethanol mixed solution, and an aqueous solution of sodium lauryl sulfate and egg yolk lecithin was added thereto, and the mixture was uniformly mixed for use.
  • the crospovidone (I) was added to the fluidized bed, and the prepared solution was sprayed into the fluidized bed by a spray gun to be granulated, and dried to obtain a solid dispersion of alimentate; further XRD test found that Alisha The active ingredient of the tanzanide was highly dispersed in the solid dispersion, demonstrating that the preparation of the solid dispersion was as expected.
  • the solid dispersion is uniformly mixed with the external auxiliary material, and the tablet is prepared by tableting, and the film composition is coated to obtain a pharmaceutical composition of alisartan.
  • the drug and povidone k29/32 were dissolved in an appropriate amount of a dichloromethane-ethanol mixed solution, and then an aqueous solution of sodium lauryl sulfate was added thereto, and the mixture was uniformly mixed.
  • the crospovidone (I) was added to the fluidized bed, and the prepared solution was sprayed into the fluidized bed by a spray gun to be granulated, and dried to obtain a solid dispersion of alimentate; further XRD test found that Alisha The active ingredient of the tanzanide was highly dispersed in the solid dispersion, demonstrating that the preparation of the solid dispersion was as expected.
  • the solid dispersion is uniformly mixed with the external auxiliary material, and the tablet is prepared by tableting, and the film composition is coated to obtain a pharmaceutical composition of alisartan.
  • the drug and povidone k29/32 are dissolved in an appropriate amount of dichloromethane-ethanol mixed solution, and then egg yolk lecithin is added, dissolved and mixed uniformly, and used.
  • the microcrystalline cellulose and crospovidone (I) are added to a fluidized bed, and the prepared solution is sprayed into a fluidized bed by a spray gun to be granulated, and dried to obtain a solid dispersion of alisartan ester; further XRD
  • the experimental results showed that the active ingredient of alisartan was highly dispersed in the solid dispersion, which proved that the preparation effect of the solid dispersion was as expected.
  • the solid dispersion is uniformly mixed with the external auxiliary material, and the tablet is prepared by tableting, and the film composition is coated to obtain a pharmaceutical composition of alisartan.
  • the drug and PEG6000 are dissolved in an appropriate amount of dichloromethane-ethanol mixed solution, then soy lecithin is added, dissolved and mixed uniformly, and used.
  • Microcrystalline cellulose and sodium carboxymethyl starch (I) are added to a fluidized bed, and the prepared solution is sprayed into a fluidized bed by a spray gun to be granulated, and dried to obtain a solid dispersion of alimentate; further XRD
  • the experimental results showed that the active ingredient of alisartan was highly dispersed in the solid dispersion, which proved that the preparation effect of the solid dispersion was as expected.
  • the solid dispersion is uniformly mixed with the external auxiliary material, and the tablet is prepared by tableting, and the film composition is coated to obtain a pharmaceutical composition of alisartan.
  • the drug and copovidone S630 are dissolved in an appropriate amount of dichloromethane-ethanol mixed solution, and then added to Tween 20, stirred and mixed uniformly, and used.
  • the microcrystalline cellulose was added to the fluidized bed, and the prepared solution was sprayed into the fluidized bed by a spray gun to be granulated, and dried to obtain a solid dispersion of alimentate; further XRD test found that the active ingredient of alisartan Highly dispersed in solid dispersion, demonstrating solid dispersion The preparation effect of the body was as expected.
  • the solid dispersion is uniformly mixed with the external auxiliary material, and the tablet is prepared by tableting, and the film composition is coated to obtain a pharmaceutical composition of alisartan.
  • the drug and hydroxypropylcellulose SL are dissolved in an appropriate amount of a dichloromethane-ethanol mixed solution, and then sucrose stearate is added, dissolved and uniformly mixed, and used.
  • the microcrystalline cellulose was added to the fluidized bed, and the prepared solution was sprayed into the fluidized bed by a spray gun to be granulated, and dried to obtain a solid dispersion of alimentate; further XRD test found that the active ingredient of alisartan Highly dispersed in the solid dispersion, demonstrating that the solid dispersion preparation effect is expected.
  • the solid dispersion is uniformly mixed with the external auxiliary material, and the tablet is prepared by tableting, and the film composition is coated to obtain a pharmaceutical composition of alisartan.
  • the drug and HPMCP HP-55 were dissolved in an appropriate amount of dichloromethane-ethanol mixed solution, and then polyoxyethylene 40 hydrogenated castor oil was added, stirred and mixed well, and used.
  • the crospovidone (I) was added to the fluidized bed, and the prepared solution was sprayed into the fluidized bed by a spray gun to be granulated, and dried to obtain a solid dispersion of alimentate; further XRD test found that Alisha The active ingredient of the tanzanide was highly dispersed in the solid dispersion, demonstrating that the preparation of the solid dispersion was as expected.
  • the solid dispersion is uniformly mixed with the external auxiliary material, and the tablet is prepared by tableting, and the film composition is coated to obtain a pharmaceutical composition of alisartan.
  • the drug and povidone k29/32 were dissolved in an appropriate amount of a dichloromethane-ethanol mixed solution, and then added to the Span 20, stirred and mixed well, and used.
  • the crospovidone (I) was added to the fluidized bed, and the prepared solution was sprayed into the fluidized bed by a spray gun to be granulated, and dried to obtain a solid dispersion of alimentate; further XRD test found that Alisha The active ingredient of the tanzanide was highly dispersed in the solid dispersion, demonstrating that the preparation of the solid dispersion was as expected.
  • the solid dispersion is uniformly mixed with the external auxiliary material, and the tablet is prepared by tableting, and the film composition is coated to obtain a pharmaceutical composition of alisartan.
  • the crospovidone (I) was added to the fluidized bed, and the prepared solution was sprayed into the fluidized bed by a spray gun to be granulated, and dried to obtain a solid dispersion of alimentate; further XRD test found that Alisha The active ingredient of the tanzanide was highly dispersed in the solid dispersion, demonstrating that the preparation of the solid dispersion was as expected.
  • the solid dispersion is uniformly mixed with the external auxiliary material, and the tablet is prepared by tableting, and the film composition is coated to obtain a pharmaceutical composition of alisartan.
  • the drug and povidone k29/32 were dissolved in an appropriate amount of a dichloromethane-ethanol mixed solution, and then sodium hexadecyl sulfate was added thereto, dissolved and uniformly mixed, and used.
  • the microcrystalline cellulose and crospovidone (I) are added to a fluidized bed, and the prepared solution is sprayed into a fluidized bed by a spray gun to be granulated, and dried to obtain a solid dispersion of alisartan ester; further XRD
  • the experimental results showed that the active ingredient of alisartan was highly dispersed in the solid dispersion, which proved that the preparation effect of the solid dispersion was as expected.
  • the solid dispersion is uniformly mixed with the external auxiliary material, and the tablet is prepared by tableting, and the film composition is coated to obtain a pharmaceutical composition of alisartan.
  • the solid dispersion is uniformly mixed with the external auxiliary material, and the tablet is prepared by tableting, and the film composition is coated to obtain a pharmaceutical composition of alisartan.
  • the solid dispersion is uniformly mixed with the external auxiliary material, and the tablet is prepared by tableting, and the film composition is coated to obtain a pharmaceutical composition of alisartan.
  • the drug and povidone k29/32 were dissolved in an appropriate amount of a dichloromethane-ethanol mixed solution, and then poloxamer 188 was added, dissolved and uniformly mixed, and used.
  • the microcrystalline cellulose and crospovidone (I) are added to the fluidized bed, and the prepared solution is sprayed into the fluidized bed by a spray gun to be granulated, and dried to obtain alisartan Solid dispersion.
  • the solid dispersion is uniformly mixed with the external auxiliary material, and the tablet is prepared by tableting, and the film composition is coated to obtain a pharmaceutical composition of alisartan.
  • the drug and copovidone are dissolved in an appropriate amount of dichloromethane-ethanol mixed solution, and then Tween 20 is added, stirred and mixed uniformly, and used.
  • the microcrystalline cellulose was added to the fluidized bed, and the prepared solution was sprayed into the fluidized bed by a spray gun to be granulated, and dried to obtain a solid dispersion of alimentate; further XRD test found that the active ingredient of alisartan Highly dispersed in the solid dispersion, demonstrating that the solid dispersion preparation effect is expected.
  • the solid dispersion is uniformly mixed with the external auxiliary material, and the tablet is prepared by tableting, and the film composition is coated to obtain a pharmaceutical composition of alisartan.
  • Example 1 87% 93% 95%
  • Example 2 90% 94% 95%
  • Example 3 93% 98% 98%
  • Example 4 91% 95% 96%
  • Example 5 87% 92% 95%
  • Example 6 86% 93% 95%
  • Example 7 85% 92% 95%
  • Example 8 90% 97% 97%
  • Example 10 90% 95% 98% Comparative Example 1 85% 93% 96% Comparative Example 2 86% 90% 96% Comparative Example 3 64% 73% 75% Comparative Example 4 84% 90% 92%
  • the pharmaceutical compositions of the alisartans esters obtained in Examples 1 to 10 and Comparative Examples 1, 2, and 4 can achieve a dissolution rate of 90% or more in 45 minutes.
  • Comparative Example 2 Except that the surfactant of the present invention was not added, the amount of the active drug and other excipients was the same as in Example 3, and the dissolution rate in 45 minutes was lower than that in the pharmaceutical composition of the alimentate of Example 3 at 45 minutes.
  • Comparative Example 4 In addition to the amount of surfactant used in the present invention, the amount of active drug and other excipients was the same as in Example 5, and the dissolution rate of the compound was lower than that of the pharmaceutical composition of Example 5 in 45 minutes. The dissolution rate at 45 minutes; Comparative Example 3, since the surfactants enumerated in the present invention were not used, the dissolution rate of the drug was rather lowered, which did not meet the clinical medicinal requirements.
  • the addition of the surfactant of the present invention contributes to the improvement of the dissolution of the pharmaceutical composition of alisartan.
  • Example 1 83% 92% 95% Comparative Example 2 55% 60% 63% Comparative Example 3 50% 55% 56% Comparative Example 4 80% 82% 85%
  • the comparative example wherein the comparative example 1 is the formulation of the example D5 in the patent CN200880001668.0, the formulation disclosed in the prior art has a large mass (912 mg), although the dissolution performance and stability both meet the medicinal requirements. Patient medication is low;
  • Comparative Example 2 compared with the formulation of Example 3, no surfactant was added. Correspondingly, the anti-aging property of the preparation obtained in Comparative Example 2 was significantly decreased, which did not meet the medicinal requirements;
  • Example 4 For Comparative Example 4, the amount of surfactant added was too small compared to Example 5, and correspondingly, although the obtained preparation had certain anti-aging ability, the dissolution property was changed too much, and the quality of the preparation was excessively fluctuated. Does not meet the medicinal requirements.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

一种阿利沙坦酯固体分散体及含有该固体分散体的药物组合物和应用。该阿利沙坦酯固体分散体由阿利沙坦酯和药学上可接受的载体材料组成，所述载体材料包含增溶载体和表面活性剂，且阿利沙坦酯与表面活性剂的质量比为1:0.01-0.10。

Description

一种阿利沙坦酯固体分散体及含有该固体分散体的药物组合物 技术领域
本发明属于药物制剂领域，特别的，本发明涉及一种阿利沙坦酯固体分散体及含有该固体分散体的药物组合物。
背景技术
阿利沙坦酯(CAS：947331-05-7)，化学名：2-丁基-4-氯-1-[2’-(1H-四唑-5-基)-1,1’-联苯基-甲基]-咪唑-5-羧酸,1-[(异丙氧基)-羰氧基]-甲酯，商品名：信立坦，是一种新型的血管紧张素Ⅱ受体拮抗剂。中国专利CN200680000397.8公开了阿利沙坦酯化合物的结构式，阿利沙坦酯毒性小，降压效果优于同类型产品(如氯沙坦)，其通过在体内代谢生成活性代谢产物(EXP3174)，从而发挥其降压作用。阿利沙坦酯属于EXP3174的酯类衍生物，其在水中的溶解度较小，采用常规制剂方法所得制剂难以满足临床用药需求。
Figure PCTCN2015082994-appb-000001
为了克服阿利沙坦酯溶解度小的缺陷，中国专利CN200880001668.0提供了一种阿利沙坦酯的药用组合物，通过加入特定载体并且使用固体分散技术有效增大了有效成分的溶出度，实施例D1-D6结果显示，45分钟时的溶出度均在90％以上，符合临床给药要求。但是，现有技术中的制剂方案存在不足，表现在所述固体分散体载药量不高，使得有效成分在药物组合物中含量较低，进而单位制剂质量偏大，使得患者的用药依从性差，也未实现临床给药质量与降压效果的最优化。
因此，提高固体分散体载药量，进而降低单位制剂质量是首先需要解决的技术问题。但是降低单位制剂质量存在技术难度，本领域公知，固体分散体是通过将有效成分以微晶、无定形或分子的形态高度分散在载体材料中，从而提高药物的溶出度。但是受到处方或储存条件等因素的影响，固体分散体中的有效成分在储存过程中不可避免的会出现或快或慢的聚集、析晶现象，即固体分散体的“老化现象”，表现为制备初始溶出性能合格的制剂，在储存一段时间后溶出性能明显下降，当固体分散体载体用量减少时，老化现象尤为明显。可以看出，固体分散体老化的快慢及程度是评价固体分散体质量的重要因素，也是提高载药量过程中需要重点考量的因素。
因此，在保证制剂溶出度，并避免“老化现象”发生的前提下，提高有效成分在固体分散体和制剂中的含量，进而降低单位制剂质量，提高患者用药依从性是现有技术未解决的技术问题。本发明从现有技术的不足出发，通过大量实验发现了一种新的阿利沙坦酯固体分散体，所述固体分散体具有稳定性高、溶出性能好的特点。所述固体分散体通过加入表面活性剂有效降低了载体的用量，提高了固体分散体的药物负载量，进而也提高了有效成分在制剂中的含量，降低了单位制剂的质量。
发明内容
本发明的目的在于克服现有技术的不足，在保证制剂稳定性及溶出度的前提下，通过加入表面活性剂，有效提高了有效成分在固体分散体中的含量，进而发现了一种高负载的阿利沙坦酯固体分散体，该固体分散体的药物负载量高于现有技术，并且含有该固体分散体的药物组合物具有溶出性能好，稳定性好等特点，符合临床用药的要求，并实现了临床给药质量与降压效果的优化，提高了患者用药依从性。
所述固体分散体的上述有益效果通过如下技术手段实现：
一种阿利沙坦酯固体分散体，由阿利沙坦酯和药学上可接受的载体材料组成，所述载体材料包含增溶载体，其特征在于所述阿利沙坦酯固体分散体还含有表面活性剂，且阿利沙坦酯与表面活性剂的质量比为1：0.01～0.10。
本领域公知，固体分散体是通过制剂手段将有效成分以微晶、无定形或分子的形态高度分散在载体材料中，从而达到提高药物溶出度的目的。但是，当 仅使用制剂手段无法使得制剂溶解度满足临床用药要求时，则需要进一步加入具有增溶效果的药用辅料以提高药物溶出度，表面活性剂即是常用的增溶药用辅料之一。
本领域公知，表面活性剂指代一类具有强表面活性，能显著降低液体表面张力的物质。根据极性基团的解离性质分类，制剂领域常用的表面活性剂包括：阴离子型表面活性剂、阳离子型表面活性剂、两性离子表面活性剂和非离子表面活性剂等。对于本方案，在制剂过程中，发明人发现：适量表面活性剂的加入可以提高制剂的溶出性能，降低增溶辅料的使用量。更令人惊奇的是，发明人通过实验发现，对于阿利沙坦酯化合物，适量表面活性剂还具有提高固体分散体稳定性的作用。具体的，表面活性剂的使用可以稳定固体分散体，减慢固体分散体的老化速度。对于本案，为达到预期的技术效果，所述表面活性剂选自阴离子型表面活性剂如十二烷基硫酸钠、十六烷基硫酸钠、十八烷基硫酸钠；两性离子表面活性剂如卵磷脂(大豆卵磷脂、蛋黄卵磷脂)；非离子表面活性剂如多元醇型(蔗糖硬脂酸酯)、脂肪酸山梨坦(司盘20、40、60、80)、聚山梨酯(吐温20、40、60、80)、聚氧乙烯脂肪醇醚类(聚氧乙烯35蓖麻油、聚氧乙烯40氢化蓖麻油)中的一种或两种以上的混合物，优选十二烷基硫酸钠、卵磷脂(大豆卵磷脂、蛋黄卵磷脂)、蔗糖硬脂酸酯、司盘20、吐温20、吐温80、聚氧乙烯40氢化蓖麻油等中的一种或两种以上的混合物。
对于阿利沙坦酯产品，表面活性剂的用量与固体分散体的药物负载量及稳定性存在一定关联。载药量，即药物负载量，指固体分散体中单位质量载体负载有效成分的量，固体分散体载药量越高，则在技术上实现的难度越大。具体的，对于本发明，在一定量的范围内，表面活性剂的加入可以明显提高溶出度、减少载体用量、避免老化现象，进而实现提高固体分散体的药物负载量，降低单位制剂质量的效果；但是随着表面活性剂的增加，其对于溶出度的提高及药物负载量的提高所起作用逐渐减弱，达到一定程度后反而会降低药物负载量。发明人通过大量实验筛选发现，对于阿利沙坦酯产品，当阿利沙坦酯与表面活性剂的质量比为1：0.01～0.10，优选1：0.02～0.06时，固体分散体稳定性及溶出度较好，且固体分散体的药物负载量可以得到明显提高。
本发明所述的药学上可接受的载体材料含有增溶载体。一般的，固体分散体中载体材料用量的增大有助于有效成分均匀、稳定的分散，从而达到提高药 物溶出度的目的，对应固体分散体的制备难度也随之降低。本发明所述固体分散体中，载体的用量可以是本领域普通技术人员公知的可实现固体分散体负载效果的用量。但是，随着表面活性剂的加入，可以在保证固体分散体稳定的基础上，明显减少固体分散体中载体的用量，进而提高固体分散体的药物负载量。
本发明所述增溶载体即可起到分散作用的载体，其指代一系列具有增溶作用的药用辅料，具体的，所述增溶载体选自聚维酮、共聚维酮等乙烯基吡咯烷酮的均聚物或共聚物；聚乙烯醇；聚乙二醇(PEG4000、PEG6000)；甲基纤维素、羟丙基纤维素、羟丙甲基纤维素等纤维素醚类；Eugragit L 100和S100、II、III号丙烯酸树脂等聚丙烯酸系聚合物；羟丙基甲基纤维素邻苯二甲酸酯(HPMCP HP-55)，醋酸纤维素邻苯二甲酸酯(CAP)、羟丙基甲基纤维素醋酸琥珀酸酯(HPMCAS)等中的一种或两种以上以任意比例混合的混合物，优选聚维酮、共聚维酮、聚乙二醇(PEG4000、PEG6000)、羟丙基纤维素、羟丙甲基纤维素、羟丙基甲基纤维素邻苯二甲酸酯(HPMCP HP-55)中的一种或两种以上以任意比例混合的混合物。尽管提高增溶载体用量有利于固体分散体的制备，但是也对应降低了固体分散体的载药量。在加入表面活性剂的前提下，阿利沙坦酯固体分散体中增溶载体的使用量可以明显减少，但是过低的增溶载体用量无法实现分散效果，进而无法形成固体分散体。更具体的，发明人经过大量实验发现，在加入表面活性剂的基础上，当所述阿利沙坦酯与增溶载体的质量比为1：0.15～0.5，优选1：0.20～0.30时，有利于实现固体分散体载药量和固体分散体产品质量的优化。
其中，所述聚维酮为1-乙烯基-2-吡咯烷酮均聚物，其规格以平均分子量分类有PVP k12、PVP k15、PVP k17、PVP k25、PVP k30、PVP k29/32、PVP k60、PVP k120等，优选PVP k29/32。所述羟丙基纤维素，其规格以平均分子量分类有HPC-SSL、HPC-SL、HPC-L、HPC-M、HPC-H等，优选HPC-SL。所述羟丙基甲基纤维素，其规格以粘度分类有E3、E5、E6、E15、E50Lv等，优选HPMC E6。
更进一步的，视处方及制备方法的需要，所述阿利沙坦酯固体分散体的载体材料可以进一步包含赋形剂，所述赋形剂的作用在于承载并辅助分散有效成分，但是过少的赋形剂无法起到承载和辅助分散的作用，而过多的赋形剂则同样会使得制剂质量偏大，同时，也会使得制剂工艺复杂化。具体的，所述赋形 剂可为崩解剂、填充剂、粘合剂等除增溶载体和表面活性剂外的药用辅料的任意一种或一种以上以任意比例混合的混合物，更具体的，所述赋形剂选自交联聚维酮、交联羧甲基纤维素钠、低取代羟丙基纤维素、羧甲基淀粉钠、微晶纤维素、淀粉、预胶化淀粉、乳糖、糊精、甘露醇、硫酸钙、磷酸钙、磷酸氢钙等中的一种或两种以上以任意比例混合的混合物，优选交联聚维酮，所述交联聚维酮为合成交联N-乙烯基-2-吡咯烷酮均聚物，规格有PVPP XL、PVPP XL-10等。所述阿利沙坦酯与赋形剂的质量比为1：0.10～1.00，优选1：0.30～0.80。
所述表面活性剂、增溶载体及赋形剂可以视需要在上述的对应种类中选择，例如，本发明所述固体分散体的一个优选技术方案，其组成如下：
组分 质量(份)
阿利沙坦酯 1
十二烷基硫酸钠 0.01
蛋黄卵磷脂 0.01
聚维酮k29/32 0.35
交联聚维酮 0.35
本发明所述固体分散体的一个优选技术方案，其组成如下：
组分 质量(份)
阿利沙坦酯 1
十二烷基硫酸钠 0.025
聚维酮k29/32 0.20
交联聚维酮 0.40
本发明所述固体分散体的一个优选技术方案，其组成如下：
组分 质量(份)
阿利沙坦酯 1
蛋黄卵磷脂 0.05
聚维酮k29/32 0.30
微晶纤维素 0.30
交联聚维酮 0.05
本发明所述固体分散体的一个优选技术方案，其组成如下：
组分 质量(份)
阿利沙坦酯 1
大豆卵磷脂 0.05
PEG6000 0.25
羧甲基淀粉钠(I) 0.10
微晶纤维素 0.40
本发明所述固体分散体的一个优选技术方案，其组成如下：
组分 质量(份)
阿利沙坦酯 1
吐温20 0.02
共聚维酮S630 0.35
微晶纤维素 0.45
本发明所述固体分散体的一个优选技术方案，其组成如下：
组分 质量(份)
阿利沙坦酯 1
蔗糖硬脂酸酯 0.06
羟丙基纤维素SL 0.375
微晶纤维素 0.37
本发明所述固体分散体的一个优选技术方案，其组成如下：
组分 质量(份)
阿利沙坦酯 1
聚氧乙烯40氢化蓖麻油 0.035
HPMCP HP-55 0.40
交联聚维酮 0.35
本发明所述固体分散体的一个优选技术方案，其组成如下：
组分 质量(份)
阿利沙坦酯 1
司盘20 0.055
聚维酮k29/32 0.20
交联聚维酮 0.40
所述阿利沙坦酯固体分散体可以视具体的处方情况采用本领域常规的制备方法制备得到，如溶剂法、溶剂沉积法、喷雾干燥法、流化床法、冷冻干燥法等，优选流化床法。
本发明说明书的一个优选技术方案中，阿利沙坦酯固体分散体的制备方法包含以下步骤：
1、将阿利沙坦酯和增溶载体溶解于适量的有机溶剂中，再加入表面活性剂混合均匀，配成药物溶液；
2、将赋形剂置于流化床中，以顶喷方式加入药物溶液，进行流化床喷雾制粒得到所述阿利沙坦酯固体分散体。
本发明的另一目的在于提供一种阿利沙坦酯药物组合物，所述药物组合物由本发明所述的阿利沙坦酯固体分散体与药用辅料组成。视制剂的需要，所述药用辅料可以包含崩解剂、粘合剂、填充剂、润滑剂等中的一种或两种以上的混合物。
所述崩解剂选自交联羧甲基纤维素钠、干淀粉、交联聚维酮、羧甲基淀粉钠、低取代羟丙基纤维素、淀粉、预胶化淀粉等中的一种或多种的混合物；所用崩解剂的量以本领域公知的能实现崩解效果的量为准，对于阿利沙坦酯药物组合物，过多崩解剂的使用不利于实现单位剂型质量的控制，而过少崩解剂的使用则使得组合物崩解实现过长，对应药物组合物的溶出无法达到临床用药的要求。优选的，所述药物组合物中固体分散体与崩解剂的质量比为1：0.02～0.20。
所述粘合剂可以视制剂处方的需要选择添加或不添加，具体的，所述粘合剂选自羟丙甲基纤维素、羟丙基纤维素、羧甲基纤维素钠、聚维酮、淀粉浆、明胶等中的一种或多种的混合物。当加入粘合剂时，所用粘合剂的量以本领域公知的能实现粘合效果的量为准，优选的，所述药物组合物中固体分散体与粘合剂的质量比为1：0.01～0.05。
所述填充剂可以视制剂处方的需要选择添加或不添加，具体的，所述填充剂选自乳糖、甘露醇、糊精、微晶纤维素、淀粉、预胶化淀粉、硫酸钙、磷酸钙、磷酸氢钙等中的一种或多种的混合物，所用填充剂的量以本领域公知的能实现填充效果的量为准，优选的，所述药物组合物中固体分散体与填充剂的质量比为1：0.02～0.20。
所述润滑剂选自硬脂酸、硬脂酸镁、微粉硅胶、滑石粉、聚乙二醇等中的一种或多种的混合物，所用润滑剂的量以本领域公知的能实现润滑效果的量为准。
所述阿利沙坦酯药物组合物为片剂、胶囊剂、颗粒剂、丸剂等常规口服制剂，优选片剂和胶囊剂。
所述药物组合物采用本领域常用的制剂手段制备，具体的，对于片剂，可以采用干法制粒、湿法制粒的方法制备，也可以采用直压的方法制备；对于胶囊剂，可以采用干法制粒、湿法制粒或采用粉末直接填装的方法。
本发明所述阿利沙坦酯药物组合物一个具体的方案，其处方及制备方法如下：
组分 质量(份)
固体分散体 1
交联聚维酮 0.09
硬脂酸镁 0.01
欧巴代 0.02
将制得固体分散体与辅料混合均匀，直接压制成片。如有需要，可以进一步包衣得到包衣片剂。
本发明所述阿利沙坦酯药物组合物可用于高血压及其并发症的治疗，优选的，所述阿利沙坦酯药物组合物可用于轻、中度原发性高血压的治疗。所述高血压并发症指代由高血压引起的病症，包括：心脏并发症，如左心室肥厚、心绞痛、心肌梗死、心力衰竭等；脑卒中，如出血性脑卒中、缺血性脑卒中、高血压脑病等；高血压性肾损害，如进展缓慢的小动脉性肾硬化症、恶性小动脉性肾硬化症、慢性肾功能衰竭等；眼科疾病，如视网膜动脉硬化、眼底改变等。
本发明与现有技术相比具有如下突出的优点及有益效果：
1、提供了一种高载药量阿利沙坦酯固体分散体，通过加入表面活性剂使得 所述固体分散体较现有技术在药物负载量、溶出性能、稳定性等方面具有明显优势；
2、提供了一种阿利沙坦酯药物组合物，该药物组合物含有本发明所述的阿利沙坦酯固体分散体，具有溶出性能好、稳定性高的特点，实现了临床给药量与降压效果的进一步优化。
具体实施方式
下面结合实施例对本发明作进一步详细的描述，但发明的实施方式不限于此。
实施例1
处方：
Figure PCTCN2015082994-appb-000002
制备：
1、固体分散体的制备
将药物和聚维酮k29/32溶解在适量二氯甲烷-乙醇混合溶液中，再加入十二烷基硫酸钠和蛋黄卵磷脂的水溶液，混合均匀，备用。将交联聚维酮(I)加入流化床中，用喷枪将配制的溶液以顶喷方式喷入流化床中制粒，干燥得到阿利沙坦酯固体分散体；进一步XRD实验检测发现，阿利沙坦酯有效成分高度分散在固体分散体中，证明固体分散体制备效果达到预期。
2、药物组合物的制备
将固体分散体与外加辅料混合均匀，压片制得素片，薄膜包衣后得到阿利沙坦酯药物组合物。
实施例2
处方：
Figure PCTCN2015082994-appb-000003
制备：
1、固体分散体的制备
将药物和聚维酮k29/32溶解在适量二氯甲烷-乙醇混合溶液中，再加入十二烷基硫酸钠水溶液，混合均匀，备用。将交联聚维酮(I)加入流化床中，用喷枪将配制的溶液以顶喷方式喷入流化床中制粒，干燥得到阿利沙坦酯固体分散体；进一步XRD实验检测发现，阿利沙坦酯有效成分高度分散在固体分散体中，证明固体分散体制备效果达到预期。
2、药物组合物的制备
将固体分散体与外加辅料混合均匀，压片制得素片，薄膜包衣后得到阿利沙坦酯药物组合物。
实施例3
处方：
Figure PCTCN2015082994-appb-000004
Figure PCTCN2015082994-appb-000005
制备：
1、固体分散体的制备
将药物和聚维酮k29/32溶解在适量二氯甲烷-乙醇混合溶液中，再加入蛋黄卵磷脂，溶解并混合均匀，备用。将微晶纤维素和交联聚维酮(I)加入流化床中，用喷枪将配制的溶液以顶喷方式喷入流化床中制粒，干燥得到阿利沙坦酯固体分散体；进一步XRD实验检测发现，阿利沙坦酯有效成分高度分散在固体分散体中，证明固体分散体制备效果达到预期。
2、药物组合物的制备
将固体分散体与外加辅料混合均匀，压片制得素片，薄膜包衣后得到阿利沙坦酯药物组合物。
实施例4
处方：
Figure PCTCN2015082994-appb-000006
Figure PCTCN2015082994-appb-000007
制备：
1、固体分散体的制备
将药物和PEG6000溶解在适量二氯甲烷-乙醇混合溶液中，再加入大豆卵磷脂，溶解并混合均匀，备用。将微晶纤维素和羧甲基淀粉钠(I)加入流化床中，用喷枪将配制的溶液以顶喷方式喷入流化床中制粒，干燥得到阿利沙坦酯固体分散体；进一步XRD实验检测发现，阿利沙坦酯有效成分高度分散在固体分散体中，证明固体分散体制备效果达到预期。
2、药物组合物的制备
将固体分散体与外加辅料混合均匀，压片制得素片，薄膜包衣后得到阿利沙坦酯药物组合物。
实施例5
处方：
Figure PCTCN2015082994-appb-000008
制备：
1、固体分散体的制备
将药物和共聚维酮S630溶解在适量二氯甲烷-乙醇混合溶液中，再加入吐温20，搅拌混合均匀，备用。将微晶纤维素加入流化床中，用喷枪将配制的溶液以顶喷方式喷入流化床中制粒，干燥得到阿利沙坦酯固体分散体；进一步XRD实验检测发现，阿利沙坦酯有效成分高度分散在固体分散体中，证明固体分散 体制备效果达到预期。
2、药物组合物的制备
将固体分散体与外加辅料混合均匀，压片制得素片，薄膜包衣后得到阿利沙坦酯药物组合物。
实施例6
处方：
Figure PCTCN2015082994-appb-000009
制备：
1、固体分散体的制备
将药物和羟丙基纤维素SL溶解在适量二氯甲烷-乙醇混合溶液中，再加入蔗糖硬脂酸酯，溶解并混合均匀，备用。将微晶纤维素加入流化床中，用喷枪将配制的溶液以顶喷方式喷入流化床中制粒，干燥得到阿利沙坦酯固体分散体；进一步XRD实验检测发现，阿利沙坦酯有效成分高度分散在固体分散体中，证明固体分散体制备效果达到预期。
2、药物组合物的制备
将固体分散体与外加辅料混合均匀，压片制得素片，薄膜包衣后得到阿利沙坦酯药物组合物。
实施例7
处方：
Figure PCTCN2015082994-appb-000010
Figure PCTCN2015082994-appb-000011
制备：
1、固体分散体的制备
将药物和HPMCP HP-55溶解在适量二氯甲烷-乙醇混合溶液中，再加入聚氧乙烯40氢化蓖麻油，搅拌混合均匀，备用。将交联聚维酮(I)加入流化床中，用喷枪将配制的溶液以顶喷方式喷入流化床中制粒，干燥得到阿利沙坦酯固体分散体；进一步XRD实验检测发现，阿利沙坦酯有效成分高度分散在固体分散体中，证明固体分散体制备效果达到预期。
2、药物组合物的制备
将固体分散体与外加辅料混合均匀，压片制得素片，薄膜包衣后得到阿利沙坦酯药物组合物。
实施例8
处方：
Figure PCTCN2015082994-appb-000012
Figure PCTCN2015082994-appb-000013
制备：
1、固体分散体的制备
将药物和聚维酮k29/32溶解在适量二氯甲烷-乙醇混合溶液中，再加入司盘20，搅拌混合均匀，备用。将交联聚维酮(I)加入流化床中，用喷枪将配制的溶液以顶喷方式喷入流化床中制粒，干燥得到阿利沙坦酯固体分散体；进一步XRD实验检测发现，阿利沙坦酯有效成分高度分散在固体分散体中，证明固体分散体制备效果达到预期。
2、药物组合物的制备
将固体分散体与外加辅料混合均匀，压片制得素片，薄膜包衣后得到阿利沙坦酯药物组合物。
实施例9
处方：
Figure PCTCN2015082994-appb-000014
制备：
1、固体分散体的制备
将药物和聚维酮k29/32溶解在适量二氯甲烷-乙醇混合溶液中，再加入十八 烷基硫酸钠水溶液，混合均匀，备用。将交联聚维酮(I)加入流化床中，用喷枪将配制的溶液以顶喷方式喷入流化床中制粒，干燥得到阿利沙坦酯固体分散体；进一步XRD实验检测发现，阿利沙坦酯有效成分高度分散在固体分散体中，证明固体分散体制备效果达到预期。
2、药物组合物的制备
将固体分散体与外加辅料混合均匀，压片制得素片，薄膜包衣后得到阿利沙坦酯药物组合物。
实施例10
处方：
Figure PCTCN2015082994-appb-000015
制备：
2、固体分散体的制备
将药物和聚维酮k29/32溶解在适量二氯甲烷-乙醇混合溶液中，再加入十六烷基硫酸钠，溶解并混合均匀，备用。将微晶纤维素和交联聚维酮(I)加入流化床中，用喷枪将配制的溶液以顶喷方式喷入流化床中制粒，干燥得到阿利沙坦酯固体分散体；进一步XRD实验检测发现，阿利沙坦酯有效成分高度分散在固体分散体中，证明固体分散体制备效果达到预期。
2、药物组合物的制备
将固体分散体与外加辅料混合均匀，压片制得素片，薄膜包衣后得到阿利沙坦酯药物组合物。
对比实施例1
处方：
Figure PCTCN2015082994-appb-000016
制备：
1、固体分散体的制备
将药物和聚维酮k29/32溶解在适量二氯甲烷-乙醇混合溶液中，将交联聚维酮(I)加入流化床中，用喷枪将配制的溶液以顶喷方式喷入流化床中制粒，干燥得到阿利沙坦酯固体分散体；进一步XRD实验检测发现，阿利沙坦酯有效成分高度分散在固体分散体中，证明固体分散体制备效果达到预期。
2、药物组合物的制备
将固体分散体与外加辅料混合均匀，压片制得素片，薄膜包衣后得到阿利沙坦酯药物组合物。
对比实施例2
处方：
Figure PCTCN2015082994-appb-000017
Figure PCTCN2015082994-appb-000018
制备：
1、固体分散体的制备
将药物和聚维酮k29/32溶解在适量二氯甲烷-乙醇混合溶液中，将微晶纤维素和交联聚维酮(I)加入流化床中，用喷枪将配制的溶液以顶喷方式喷入流化床中制粒，干燥得到阿利沙坦酯固体分散体；进一步XRD实验检测发现，阿利沙坦酯有效成分高度分散在固体分散体中，证明固体分散体制备效果达到预期。
2、药物组合物的制备
将固体分散体与外加辅料混合均匀，压片制得素片，薄膜包衣后得到阿利沙坦酯药物组合物。
对比实施例3
处方：
Figure PCTCN2015082994-appb-000019
制备：
1、固体分散体的制备
将药物和聚维酮k29/32溶解在适量二氯甲烷-乙醇混合溶液中，再加入泊洛沙姆188，溶解并混合均匀，备用。将微晶纤维素和交联聚维酮(I)加入流化床中，用喷枪将配制的溶液以顶喷方式喷入流化床中制粒，干燥得到阿利沙坦酯 固体分散体。
2、药物组合物的制备
将固体分散体与外加辅料混合均匀，压片制得素片，薄膜包衣后得到阿利沙坦酯药物组合物。
对比实施例4
处方：
Figure PCTCN2015082994-appb-000020
制备：
1、固体分散体的制备
将药物和共聚维酮溶解在适量二氯甲烷-乙醇混合溶液中，再加入吐温20，搅拌混合均匀，备用。将微晶纤维素加入流化床中，用喷枪将配制的溶液以顶喷方式喷入流化床中制粒，干燥得到阿利沙坦酯固体分散体；进一步XRD实验检测发现，阿利沙坦酯有效成分高度分散在固体分散体中，证明固体分散体制备效果达到预期。
2、药物组合物的制备
将固体分散体与外加辅料混合均匀，压片制得素片，薄膜包衣后得到阿利沙坦酯药物组合物。
实施例11
采用中国药典2010版附录XC溶出度测定第二法，检测实施例1～10、对比实施例1～4所得阿利沙坦酯药物组合物0天时在pH6.8磷酸盐缓冲液(37℃， 溶出介质900mL，转速50rpm)中的溶出情况，分别在15min，30min，45min取样，以紫外分光光度法测定。
项目 15min 30min 45min
实施例1 87％ 93％ 95％
实施例2 90％ 94％ 95％
实施例3 93％ 98％ 98％
实施例4 91％ 95％ 96％
实施例5 87％ 92％ 95％
实施例6 86％ 93％ 95％
实施例7 85％ 92％ 95％
实施例8 90％ 97％ 97％
实施例9 88％ 93％ 94％
实施例10 90％ 95％ 98％
对比实施例1 85％ 93％ 96％
对比实施例2 86％ 90％ 96％
对比实施例3 64％ 73％ 75％
对比实施例4 84％ 90％ 92％
从上述数据可以看出，实施例1～10以及对比实施例1、2、4所得阿利沙坦酯药物组合物可以实现45分钟的溶出度为90％以上。对比实施例2除未加本发明的表面活性剂外，活性药物及其他辅料的用量与实施例3一致，其45分钟溶出度低于实施例3的阿利沙坦酯药物组合物45分钟时的溶出度；对比实施例4除表面活性剂的用量低于本发明的用量外，活性药物及其他辅料的用量与实施例5一致，其45分钟溶出度低于实施例5的阿利沙坦酯药物组合物45分钟时的溶出度；对比实施例3，由于未使用本发明所列举的表面活性剂，而使得药物的溶出速率反而降低，不符合临床药用要求。
从上述实验结果可以看出，本发明的表面活性剂的加入有助于提高阿利沙坦酯药物组合物的溶出度。
实施例12
将实施例1～10，对比实施例1～4所得阿利沙坦酯药物组合物置于40℃高温 条件下储存30天，采用如实施例11的方法检测溶出度情况。
项目 15min 30min 45min
实施例1 85％ 96％ 96％
实施例2 89％ 95％ 95％
实施例3 95％ 97％ 98％
实施例4 90％ 95％ 96％
实施例5 83％ 89％ 91％
实施例6 85％ 92％ 95％
实施例7 83％ 90％ 93％
实施例8 89％ 95％ 96％
实施例9 84％ 87％ 91％
实施例10 88％ 95％ 97％
对比实施例1 83％ 92％ 96％
对比实施例2 55％ 60％ 63％
对比实施例3 50％ 55％ 56％
对比实施例4 80％ 82％ 85％
从上述数据可以看出，实施例1～10所得阿利沙坦酯药物组合物在40℃高温条件下储存30天后，其溶出性能没有明显的降低，可知对应的药物组合物中，固体分散体并未出现明显的老化现象；
反观对比实施例，其中对比实施例1为专利CN200880001668.0中实施例D5处方，现有技术公开的制剂尽管溶出性能及稳定性均达到药用要求，但是其单位制剂质量较大(912mg)，患者用药顺应性低；
对于对比实施例2，其与实施例3处方相比未加入表面活性剂，对应的，对比实施例2所得制剂的抗老化性能明显下降,不符合药用要求；
对于对比实施例4，其与实施例5相比加入表面活性剂的量过少，对应的，尽管其所得制剂具有一定抗老化能力，但是溶出性能还是变化过于明显，使得制剂质量波动过大，不符合药用要求。
上述实施例为本发明较佳的实施方式，但本发明的实施方式并不受上述实施例的限制，其他的任何未背离本发明的精神实质与原理下所作的改变、修饰、替代、组合、简化，均应为等效的置换方式，都包含在本发明的保护范围之内。

Claims (16)

  1. 一种阿利沙坦酯固体分散体，由阿利沙坦酯和药学上可接受的载体材料组成，所述载体材料包含增溶载体，其特征在于所述阿利沙坦酯固体分散体还含有表面活性剂，且阿利沙坦酯与表面活性剂的质量比为1：0.01～0.10。
  2. 根据权利要求1所述的一种阿利沙坦酯固体分散体，其特征在于所述表面活性剂为十二烷基硫酸钠、十六烷基硫酸钠、十八烷基硫酸钠、卵磷脂、多元醇型非离子表面活性剂、脂肪酸山梨坦、聚山梨酯、聚氧乙烯脂肪醇醚类中的一种或两种以上的混合物。
  3. 根据权利要求1-2任意一项所述的一种阿利沙坦酯固体分散体，其特征在于所述阿利沙坦酯固体分散体中，所述表面活性剂为十二烷基硫酸钠、卵磷脂、蔗糖硬脂酸酯、司盘20、吐温20、吐温80、聚氧乙烯40氢化蓖麻油中的一种或两种以上的混合物。
  4. 根据权利要求1-3任意一项所述的一种阿利沙坦酯固体分散体，其特征在于所述阿利沙坦酯固体分散体中，阿利沙坦酯与表面活性剂的质量比为1：0.02～0.06。
  5. 根据权利要求1-4任意一项所述的一种阿利沙坦酯固体分散体，其特征在于所述阿利沙坦酯固体分散体中，所述增溶载体为乙烯基吡咯烷酮的均聚物或共聚物、聚乙烯醇、聚乙二醇、纤维素醚类、聚丙烯酸系聚合物、羟丙基甲基纤维素邻苯二甲酸酯、醋酸纤维素邻苯二甲酸酯、羟丙基甲基纤维素醋酸琥珀酸酯中的一种或两种以上以任意比例混合的混合物。
  6. 根据权利要求1-5任意一项所述的一种阿利沙坦酯固体分散体，其特征在于所述阿利沙坦酯固体分散体中，所述增溶载体为聚维酮、共聚维酮、PEG4000、PEG6000、羟丙基纤维素、羟丙甲基纤维素、羟丙基甲基纤维素邻苯二甲酸酯中的一种或两种以上以任意比例混合的混合物。
  7. 根据权利要求1-6任意一项所述的一种阿利沙坦酯固体分散体，其特征在于所述阿利沙坦酯固体分散体中，所述阿利沙坦酯与增溶载体的质量比为1：0.15～0.5。
  8. 根据权利要求1-7任意一项所述的一种阿利沙坦酯固体分散体，其特征在于所述阿利沙坦酯固体分散体中，所述阿利沙坦酯与增溶载体的质量比为1：0.20～0.30。
  9. 根据权利要求1-8任意一项所述的一种阿利沙坦酯固体分散体，其特征在于所述阿利沙坦酯固体分散体中还含有赋形剂，所述阿利沙坦酯与赋形剂的质量比为1：0.10～1.00。
  10. 根据权利要求9所述的一种阿利沙坦酯固体分散体，其特征在于所述阿利沙坦酯固体分散体中，所述赋形剂为交联聚维酮、交联羧甲基纤维素钠、低取代羟丙基纤维素、羧甲基淀粉钠、微晶纤维素、淀粉、预胶化淀粉、乳糖、糊精、甘露醇、硫酸钙、磷酸钙、磷酸氢钙等中的一种或两种以上以任意比例混合的混合物。
  11. 根据权利要求9-10任意一项所述的一种阿利沙坦酯固体分散体，其特征在于所述阿利沙坦酯固体分散体中还含有赋形剂，所述阿利沙坦酯与赋形剂的质量比为1：0.30～0.80。
  12. 一种阿利沙坦酯药物组合物，其特征在于所述药物组合物由权利要求1-11任意一项所述的阿利沙坦酯固体分散体与药用辅料组成。
  13. 根据权利要求12所述的阿利沙坦酯药物组合物，其特征在于所述药用辅料包含崩解剂、粘合剂、填充剂、润滑剂中的一种或两种以上的混合物；所述崩解剂为交联羧甲基纤维素钠、交联聚维酮、羧甲基淀粉钠、低取代羟丙基纤维素、淀粉、预胶化淀粉中的一种或多种的混合物；所述粘合剂为羟丙甲基纤维素、羟丙基纤维素、羧甲基纤维素钠、聚维酮、淀粉浆、明胶等中的一种或多 种的混合物；所述填充剂为乳糖、甘露醇、糊精、微晶纤维素、淀粉、预胶化淀粉、硫酸钙、磷酸钙、磷酸氢钙等中的一种或多种的混合物；所述润滑剂为硬脂酸、硬脂酸镁、微粉硅胶、滑石粉、聚乙二醇等中的一种或多种的混合物。
  14. 根据权利要求13所述的阿利沙坦酯药物组合物，其特征在于所述药物组合物中固体分散体与崩解剂的质量比为1：0.02～0.20；所述药物组合物中固体分散体与粘合剂的质量比为1：0.01～0.05；所述药物组合物中固体分散体与填充剂的质量比为1：0.02～0.20。
  15. 根据权利要求12-14任意一项所述的阿利沙坦酯药物组合物，其特征在于所述阿利沙坦酯药物组合物为片剂、胶囊剂、颗粒剂、丸剂。
  16. 一种如12-15任意一项所述阿利沙坦酯药物组合物用于制备治疗高血压及其并发症的用途。
PCT/CN2015/082994 2014-07-01 2015-06-30 一种阿利沙坦酯固体分散体及含有该固体分散体的药物组合物 WO2016000608A1 (zh)

Priority Applications (7)

Application Number Priority Date Filing Date Title
CA2949164A CA2949164A1 (en) 2014-07-01 2015-06-30 Allisartan isoproxil solid dispersion and pharmaceutical composition comprising same
MX2016017142A MX2016017142A (es) 2014-07-01 2015-06-30 Dispersion solida de allisartan isoproxilo y composicion farmaceutica que comprende la misma.
EP15814962.5A EP3165219A4 (en) 2014-07-01 2015-06-30 Allisartan isoproxil solid dispersion and pharmaceutical composition comprising same
US15/320,478 US20170157095A1 (en) 2014-07-01 2015-06-30 Allisartan isoproxil solid dispersion and pharmaceutical composition
JP2016575770A JP6293315B2 (ja) 2014-07-01 2015-06-30 アリサルタン・イソプロキシル固体分散体及び該固体分散体を含有する医薬組成物
KR1020177000500A KR101895962B1 (ko) 2014-07-01 2015-06-30 알리사르탄 이소프록실 고체 분산체 및 이를 포함하는 약제학적 조성물
RU2017102990A RU2017102990A (ru) 2014-07-01 2015-06-30 Твёрдая дисперсия аллисартана изопроксила и фармацевтическая композиция

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201410310848.4 2014-07-01
CN201410310848 2014-07-01

Publications (1)

Publication Number Publication Date
WO2016000608A1 true WO2016000608A1 (zh) 2016-01-07

Family

ID=55018454

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2015/082994 WO2016000608A1 (zh) 2014-07-01 2015-06-30 一种阿利沙坦酯固体分散体及含有该固体分散体的药物组合物

Country Status (10)

Country Link
US (1) US20170157095A1 (zh)
EP (1) EP3165219A4 (zh)
JP (1) JP6293315B2 (zh)
KR (1) KR101895962B1 (zh)
CN (1) CN105232489B (zh)
CA (1) CA2949164A1 (zh)
MX (1) MX2016017142A (zh)
RU (1) RU2017102990A (zh)
TW (1) TWI592154B (zh)
WO (1) WO2016000608A1 (zh)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107441497A (zh) * 2016-05-31 2017-12-08 深圳信立泰药业股份有限公司 一种阿利沙坦酯固体分散体及其制备方法及含有该固体分散体的制剂
EP3746027A4 (en) * 2018-01-29 2021-12-15 Menning, Mark Michael PROCESS FOR CREATING SOLID DISPERSIONS
CN111297872B (zh) * 2020-03-02 2021-01-12 牡丹江医学院 一种治疗慢性萎缩性胃炎的药物及其制备方法
CN111419800B (zh) * 2020-04-23 2021-03-19 温州医科大学附属第二医院、温州医科大学附属育英儿童医院 用于治疗红斑狼疮的药物制剂及其制备方法
CN112089699B (zh) * 2020-09-29 2022-01-28 广东逸舒制药股份有限公司 一种氯雷他定速缓释片及其制备工艺

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101066264A (zh) * 2007-06-12 2007-11-07 杨喜鸿 奥美沙坦酯的固体分散体及其制备方法和药物应用
CN101961306A (zh) * 2009-07-24 2011-02-02 北京化工大学 一种低熔点药物固体分散体的制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1241566C (zh) * 2004-03-15 2006-02-15 深圳海王药业有限公司 西洛他唑固体分散体及其片剂制备方法
CN101214242A (zh) * 2007-01-05 2008-07-09 上海艾力斯医药科技有限公司 新的药用组合物
CN102178642A (zh) * 2011-04-29 2011-09-14 苏州大学 一种替米沙坦固体分散体及其制备方法
CN102357078A (zh) * 2011-10-17 2012-02-22 苏州大学 一种缬沙坦固体分散体及其制备方法
KR101441450B1 (ko) * 2012-10-22 2014-09-24 충남대학교산학협력단 생체 이용률이 향상된 에프로살탄 고체 분산체, 이의 제조방법 및 용도
CN105078974A (zh) * 2014-05-23 2015-11-25 深圳信立泰药业股份有限公司 一种阿利沙坦酯固体分散体及药物组合物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101066264A (zh) * 2007-06-12 2007-11-07 杨喜鸿 奥美沙坦酯的固体分散体及其制备方法和药物应用
CN101961306A (zh) * 2009-07-24 2011-02-02 北京化工大学 一种低熔点药物固体分散体的制备方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
See also references of EP3165219A4 *
SHAIKH, S.M. ET AL.: "Enhancement of Solubility and Permeability of Candesartan Cilexetil by Using Different Pharmaceutical Interventions", CURRENT DRUG DELIVERY, vol. 8, no. 4, 31 July 2011 (2011-07-31), XP008185572, ISSN: 1570-2018 *
ZHANG, GEHUI ET AL.: "Preparation Research on Immediate-Release and Sustained Release Solid Disperations of Candesartan Cilexetil", CHINA MEDICAL HERALD, vol. 10, no. 1, 31 January 2013 (2013-01-31), pages 126 - 128 and 134, XP008185587, ISSN: 1673-7210 *

Also Published As

Publication number Publication date
CN105232489B (zh) 2019-06-11
KR101895962B1 (ko) 2018-10-18
KR20170040795A (ko) 2017-04-13
MX2016017142A (es) 2017-07-28
JP6293315B2 (ja) 2018-03-14
RU2017102990A3 (zh) 2018-08-01
EP3165219A4 (en) 2017-12-27
TW201601719A (zh) 2016-01-16
TWI592154B (zh) 2017-07-21
JP2017519789A (ja) 2017-07-20
CN105232489A (zh) 2016-01-13
EP3165219A1 (en) 2017-05-10
CA2949164A1 (en) 2016-01-07
US20170157095A1 (en) 2017-06-08
RU2017102990A (ru) 2018-08-01

Similar Documents

Publication Publication Date Title
US9415053B2 (en) Solid, orally administrable pharmaceutical composition
KR101190708B1 (ko) 모사프리드 또는 이의 염을 포함하는 서방형 약학 조성물
WO2017140254A1 (zh) 一种含有jak激酶抑制剂或其可药用盐的药物组合物
KR100527985B1 (ko) 신속 발현 제제
JP5911969B2 (ja) 心臓血管障害の治療方法
TWI592154B (zh) Allisartan-based solid dispersions and pharmaceutical compositions containing the solid dispersions
WO2015176655A1 (zh) 一种阿利沙坦酯固体分散体及药物组合物
US10874618B2 (en) Compositions for treatment of heart failure in dogs
WO2018108157A1 (zh) 一种瑞卡帕布口服缓控释药物组合物及其用途
KR20170139170A (ko) 4-아미노-5-플루오로-3-[6-(4-메틸피페라진-1-일)-1ｈ-벤즈이미다졸-2-일]-1ｈ-퀴놀린-2-온 락테이트 일수화물을 포함한 제약 조성물
WO2021129735A1 (zh) 一种固体制剂及其制备方法和用途
KR20120094882A (ko) 모사프리드 또는 이의 염을 포함하는 서방형 약학 조성물
US10888524B2 (en) Immediate release tablet of dofetilide
ES2963886T3 (es) Comprimidos que contienen tamsulosina y solifenacina
US20180344648A1 (en) Clobazam tablet formulation and process for its preparation
US11260055B2 (en) Oral pharmaceutical composition of lurasidone and preparation thereof
TWI823471B (zh) 沙庫巴曲纈沙坦鈉緩釋組合物、其製備方法及應用
WO2021057881A1 (zh) 一种奥司他韦制剂
US20220202698A1 (en) Extended release pharmaceutical compositions of riociguat
CN115957189A (zh) 一种安立生坦制剂及其制备方法
EP4295839A1 (en) Combination of valsartan and indapamide
NZ623628B2 (en) Solid oral pharmaceutical formulations comprising amorphous (S)-methyl (1- ((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)phenyl)-1-isopropy1-1H-pyrazo1-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate (Compound A)
KR20110075840A (ko) 로피니롤 경구 투여용 서방성 제제

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15814962

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2949164

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: MX/A/2016/017142

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 15320478

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2016575770

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 20177000500

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2017102990

Country of ref document: RU

Kind code of ref document: A

REEP Request for entry into the european phase

Ref document number: 2015814962

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2015814962

Country of ref document: EP